Search

Your search keyword '"Salazar, Andres M."' showing total 560 results
Start Over Author "Salazar, Andres M."
560 results on '"Salazar, Andres M."'

1. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy

Author

Sultan, Hussein, Takeuchi, Yoshiko, Ward, Jeffrey P., Sharma, Naveen, Liu, Tian-Tian, Sukhov, Vladimir, Firulyova, Maria, Song, Yuang, Ameh, Samuel, Brioschi, Simone, Khantakova, Darya, Arthur, Cora D., White, J. Michael, Kohlmiller, Heather, Salazar, Andres M., Burns, Robert, Costa, Helio A., Moynihan, Kelly D., Yeung, Yik Andy, Djuretic, Ivana, Schumacher, Ton N., Sheehan, Kathleen C. F., Colonna, Marco, Allison, James P., Murphy, Kenneth M., Artyomov, Maxim N., and Schreiber, Robert D.

Published
2024
Full Text
View/download PDF

2. ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease

Author

Castro, Julia T., Brito, Rory, Hojo-Souza, Natalia S., Azevedo, Bárbara, Salazar, Natalia, Ferreira, Camila P., Junqueira, Caroline, Fernandes, Ana Paula, Vasconcellos, Ronnie, Cardoso, Jamille M., Aguiar-Soares, Rodrigo D. O., Vieira, Paula M. A., Carneiro, Cláudia M., Valiate, Bruno, Toledo, Cristiane, Salazar, Andres M., Caballero, Otávia, Lannes-Vieira, Joseli, Teixeira, Santuza R., Reis, Alexandre B., and Gazzinelli, Ricardo T.

Published
2023
Full Text
View/download PDF

4. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas

Author

Ogino, Hirokazu, Taylor, Jennie W, Nejo, Takahide, Gibson, David, Watchmaker, Payal B, Okada, Kaori, Saijo, Atsuro, Tedesco, Meghan R, Shai, Anny, Wong, Cynthia M, Rabbitt, Jane E, Olin, Michael R, Moertel, Christopher L, Nishioka, Yasuhiko, Salazar, Andres M, Molinaro, Annette M, Phillips, Joanna J, Butowski, Nicholas A, Clarke, Jennifer L, Bush, Nancy Ann Oberheim, Hervey-Jumper, Shawn L, Theodosopoulos, Philip, Chang, Susan M, Berger, Mitchel S, and Okada, Hideho

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Prevention, Vaccine Related, Cancer, Clinical Trials and Supportive Activities, Orphan Drug, Brain Cancer, Neurosciences, Immunization, Brain Disorders, Biotechnology, Rare Diseases, Evaluation of treatments and therapeutic interventions, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adult, Aged, CD8-Positive T-Lymphocytes, Cancer Vaccines, Carboxymethylcellulose Sodium, Female, Glioma, Humans, Male, Middle Aged, Neoadjuvant Therapy, Poly I-C, Polylysine, Tumor Microenvironment, Vaccination, Brain cancer, Cancer immunotherapy, Oncology, T cells, Vaccines, Medical and Health Sciences, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BACKGROUNDLong-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy.METHODSWe conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor.RESULTSA total of 17 eligible patients were enrolled - 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident-like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination.CONCLUSIONThe regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies.TRIAL REGISTRATIONClinicalTrials.gov NCT02549833.FUNDINGNIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.

Published
2022

5. IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Author

Ohkuri, Takayuki, Kosaka, Akemi, Ikeura, Maki, Salazar, Andres M, and Okada, Hideho

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Vaccine Related, Rare Diseases, Cancer, Brain Disorders, Immunization, Biotechnology, Brain Cancer, Neurosciences, 5.2 Cellular and gene therapies, Development of treatments and therapeutic interventions, CD8-Positive T-Lymphocytes, Carboxymethylcellulose Sodium, Glioma, Humans, Interferon-gamma, Interleukin-17, Poly I-C, Polylysine, Vaccines, Subunit, brain neoplasms, central nervous system neoplasms, immunotherapy, adoptive, T-Lymphocytes, vaccination, Oncology and carcinogenesis
Abstract

BackgroundWhile adoptive transfer of T-cells has been a major medical breakthrough for patients with B cell malignancies, the development of safe and effective T-cell-based immunotherapy for central nervous system (CNS) tumors, such as glioblastoma (GBM), still needs to overcome multiple challenges, including effective homing and persistence of T-cells. Based on previous observations that interleukin (IL)-17-producing T-cells can traffic to the CNS in autoimmune conditions, we evaluated CD8+ T-cells that produce IL-17 and interferon-γ (IFN-γ) (Tc17-1) cells in a preclinical GBM model.MethodsWe differentiated Pmel-1 CD8+ T-cells into Tc17-1 cells and compared their phenotypic and functional characteristics with those of IFN-γ-producing CD8+ T (Tc1) and IL-17-producing CD8+ T (Tc17) cells. We also evaluated the therapeutic efficacy, persistence, and tumor-homing of Tc17-1 cells in comparison to Tc1 cells using a mouse GL261 glioma model.ResultsIn vitro, Tc17-1 cells demonstrated profiles of both Tc1 and Tc17 cells, including production of both IFN-γ and IL-17, although Tc17-1 cells demonstrated lesser degrees of antigen-specific cytotoxic activity compared with Tc1 cells. In mice-bearing intracranial GL261-Quad tumor and treated with temozolomide, Tc1 cells, but not Tc17-1, showed a significant prolongation of survival. However, when the T-cell transfer was combined with poly-ICLC and Pmel-1 peptide vaccine, both Tc1 and Tc17-1 cells exhibited significantly prolonged survival associated with upregulation of very late activation antigen-4 on Tc17-1 cells in vivo. Glioma cells that recurred following the therapy lost the susceptibility to Pmel-1-derived cytotoxic T-cells, indicating that immuno-editing was a mechanism of the acquired resistance.ConclusionsTc17-1 cells were equally effective as Tc1 cells when combined with poly-ICLC and peptide vaccine treatment.

Published
2021

6. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

Author

Mueller, Sabine, Taitt, Jared M, Villanueva-Meyer, Javier E, Bonner, Erin R, Nejo, Takahide, Lulla, Rishi R, Goldman, Stewart, Banerjee, Anu, N., Susan, Whipple, Nicholas S, Crawford, John R, Gauvain, Karen, Nazemi, Kellie J, Watchmaker, Payal B, Almeida, Neil D, Okada, Kaori, Salazar, Andres M, Gilbert, Ryan D, Nazarian, Javad, Molinaro, Annette M, Butterfield, Lisa H, Prados, Michael D, and Okada, Hideho

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Pediatric Cancer, Brain Cancer, Clinical Trials and Supportive Activities, Pediatric, Clinical Research, Brain Disorders, Rare Diseases, Cancer, Vaccine Related, Neurosciences, Biotechnology, Orphan Drug, Immunization, 6.1 Pharmaceuticals, Good Health and Well Being, Adolescent, Adult, Amino Acid Substitution, Brain Stem Neoplasms, CD8-Positive T-Lymphocytes, Cancer Vaccines, Child, Child, Preschool, Female, Flow Cytometry, Glioma, Histones, Humans, Immunity, Cellular, Male, Mutation, Missense, Neoplasm Proteins, Brain cancer, Cancer immunotherapy, Oncology, Medical and Health Sciences, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BACKGROUNDPatients with diffuse midline gliomas (DMGs), including diffuse intrinsic pontine glioma (DIPG), have dismal outcomes. We previously described the H3.3K27M mutation as a shared neoantigen in HLA-A*02.01+, H3.3K27M+ DMGs. Within the Pacific Pediatric Neuro-Oncology Consortium, we assessed the safety and efficacy of an H3.3K27M-targeted peptide vaccine.METHODSNewly diagnosed patients, aged 3-21 years, with HLA-A*02.01+ and H3.3K27M+ status were enrolled in stratum A (DIPG) or stratum B (nonpontine DMG). Vaccine was administered in combination with polyinosinic-polycytidylic acid-poly-I-lysine carboxymethylcellulose (poly-ICLC) every 3 weeks for 8 cycles, followed by once every 6 weeks. Immunomonitoring and imaging were performed every 3 months. Imaging was centrally reviewed. Immunological responses were assessed in PBMCs using mass cytometry.RESULTSA total of 19 patients were enrolled in stratum A (median age,11 years) and 10 in stratum B (median age, 13 years). There were no grade-4 treatment-related adverse events (TRAEs). Injection site reaction was the most commonly reported TRAE. Overall survival (OS) at 12 months was 40% (95% CI, 22%-73%) for patients in stratum A and 39% (95% CI, 16%-93%) for patients in stratum B. The median OS was 16.1 months for patients who had an expansion of H3.3K27M-reactive CD8+ T cells compared with 9.8 months for their counterparts (P = 0.05). Patients with DIPG with below-median baseline levels of myeloid-derived suppressor cells had prolonged OS compared with their counterparts (P < 0.01). Immediate pretreatment dexamethasone administration was inversely associated with H3.3K27M-reactive CD8+ T cell responses.CONCLUSIONAdministration of the H3.3K27M-specific vaccine was well tolerated. Patients with H3.3K27M-specific CD8+ immunological responses demonstrated prolonged OS compared with nonresponders.TRIAL REGISTRATIONClinicalTrials.gov NCT02960230.FUNDINGThe V Foundation, the Pacific Pediatric Neuro-Oncology Consortium Foundation, the Pediatric Brain Tumor Foundation, the Mithil Prasad Foundation, the MCJ Amelior Foundation, the Anne and Jason Farber Foundation, Will Power Research Fund Inc., the Isabella Kerr Molina Foundation, the Parker Institute for Cancer Immunotherapy, and the National Institute of Neurological Disorders and Stroke (NINDS), NIH (R35NS105068).

Published
2020

9. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

Author

Bhardwaj, Nina, Friedlander, Philip A., Pavlick, Anna C., Ernstoff, Marc S., Gastman, Brian R., Hanks, Brent A., Curti, Brendan D., Albertini, Mark R., Luke, Jason J., Blazquez, Ana B., Balan, Sreekumar, Bedognetti, Davide, Beechem, Joseph M., Crocker, Andrea S., D’Amico, Leonard, Danaher, Patrick, Davis, Thomas A., Hawthorne, Thomas, Hess, Bruce W., Keler, Tibor, Lundgren, Lisa, Morishima, Chihiro, Ramchurren, Nirasha, Rinchai, Darawan, Salazar, Andres M., Salim, Bob A., Sharon, Elad, Vitale, Laura A., Wang, Ena, Warren, Sarah, Yellin, Michael J., Disis, Mary L., Cheever, Martin A., and Fling, Steven P.

Published
2020
Full Text
View/download PDF

10. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas

Author

Saijo, Atsuro, primary, Ogino, Hirokazu, additional, Butowski, Nicholas A, additional, Tedesco, Meghan R, additional, Gibson, David, additional, Watchmaker, Payal B, additional, Okada, Kaori, additional, Wang, Albert S, additional, Shai, Anny, additional, Salazar, Andres M, additional, Molinaro, Annette M, additional, Rabbitt, Jane E, additional, Shahin, Maryam, additional, Perry, Arie, additional, Clarke, Jennifer L, additional, Taylor, Jennie W, additional, Daras, Mariza, additional, Oberheim Bush, Nancy Ann, additional, Hervey-Jumper, Shawn L, additional, Phillips, Joanna J, additional, Chang, Susan M, additional, Hilf, Norbert, additional, Mayer-Mokler, Andrea, additional, Keler, Tibor, additional, Berger, Mitchel S, additional, and Okada, Hideho, additional

Published
2023
Full Text
View/download PDF

12. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4

Author

Stewart-Jones, Guillaume B. E., Chuang, Gwo-Yu, Xu, Kai, Zhou, Tongqing, Acharya, Priyamvada, Tsybovsky, Yaroslav, Ou, Li, Zhang, Baoshan, Fernandez-Rodriguez, Blanca, Gilardi, Valentina, Silacci-Fregni, Chiara, Beltramello, Martina, Baxa, Ulrich, Druz, Aliaksandr, Kong, Wing-Pui, Thomas, Paul V., Yang, Yongping, Foulds, Kathryn E., Todd, John-Paul, Wei, Hui, Salazar, Andres M., Scorpio, Diana G., Carragher, Bridget, Potter, Clinton S., Corti, Davide, Mascola, John R., Lanzavecchia, Antonio, and Kwong, Peter D.

Published
2018

13. Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC

Author

Okada, Hideho, Butterfield, Lisa H, Hamilton, Ronald L, Hoji, Aki, Sakaki, Masashi, Ahn, Brian J, Kohanbash, Gary, Drappatz, Jan, Engh, Johnathan, Amankulor, Nduka, Lively, Mark O, Chan, Michael D, Salazar, Andres M, Shaw, Edward G, Potter, Douglas M, and Lieberman, Frank S

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Neurosciences, Prevention, Immunization, Brain Cancer, Cancer, Brain Disorders, Vaccine Related, Clinical Research, Orphan Drug, Biotechnology, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Antigens, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, CD8-Positive T-Lymphocytes, Cancer Vaccines, Carboxymethylcellulose Sodium, Disease-Free Survival, Female, Glioma, Humans, Male, Middle Aged, Neoplasm Grading, Pilot Projects, Poly I-C, Polylysine, Treatment Outcome, Vaccines, Subunit, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeWHO grade 2 low-grade gliomas (LGG) with high risk factors for recurrence are mostly lethal despite current treatments. We conducted a phase I study to evaluate the safety and immunogenicity of subcutaneous vaccinations with synthetic peptides for glioma-associated antigen (GAA) epitopes in HLA-A2(+) adults with high-risk LGGs in the following three cohorts: (i) patients without prior progression, chemotherapy, or radiotherapy (RT); (ii) patients without prior progression or chemotherapy but with prior RT; and (iii) recurrent patients.Experimental designGAAs were IL13Rα2, EphA2, WT1, and Survivin. Synthetic peptides were emulsified in Montanide-ISA-51 and given every 3 weeks for eight courses with intramuscular injections of poly-ICLC, followed by q12 week booster vaccines.ResultsCohorts 1, 2, and 3 enrolled 12, 1, and 10 patients, respectively. No regimen-limiting toxicity was encountered except for one case with grade 3 fever, fatigue, and mood disturbance (cohort 1). ELISPOT assays demonstrated robust IFNγ responses against at least three of the four GAA epitopes in 10 and 4 cases of cohorts 1 and 3, respectively. Cohort 1 patients demonstrated significantly higher IFNγ responses than cohort 3 patients. Median progression-free survival (PFS) periods since the first vaccine are 17 months in cohort 1 (range, 10-47+) and 12 months in cohort 3 (range, 3-41+). The only patient with large astrocytoma in cohort 2 has been progression-free for more than 67 months since diagnosis.ConclusionThe current regimen is well tolerated and induces robust GAA-specific responses in WHO grade 2 glioma patients. These results warrant further evaluations of this approach. Clin Cancer Res; 21(2); 286-94. ©2014 AACR.

Published
2015

14. Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Virus Vaccine Assessment

Author

Skinner, Jason A, Zurawski, Sandra M, Sugimoto, Chie, Vinet-Oliphant, Heather, Vinod, Parvathi, Xue, Yaming, Russell-Lodrigue, Kasi, Albrecht, Randy A, García-Sastre, Adolfo, Salazar, Andres M, Roy, Chad J, Kuroda, Marcelo J, Oh, SangKon, and Zurawski, Gerard

Subjects
Microbiology, Biological Sciences, Rare Diseases, Vaccine Related, Emerging Infectious Diseases, Immunization, Infectious Diseases, Influenza, Pneumonia & Influenza, Biotechnology, Prevention, Biodefense, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Animals, Antibodies, Viral, Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human, Macaca mulatta, Orthomyxoviridae Infections, Vaccination, Immunology
Abstract

Despite the availability of annually formulated vaccines, influenza virus infection remains a worldwide public health burden. Therefore, it is important to develop preclinical challenge models that enable the evaluation of vaccine candidates while elucidating mechanisms of protection. Here, we report that naive rhesus macaques challenged with 2009 pandemic H1N1 (pH1N1) influenza virus do not develop observable clinical symptoms of disease but develop a subclinical biphasic fever on days 1 and 5 to 6 postchallenge. Whole blood microarray analysis further revealed that interferon activity was associated with fever. We then tested whether type I interferon activity in the blood is a correlate of vaccine efficacy. The animals immunized with candidate vaccines carrying hemagglutinin (HA) or nucleoprotein (NP) exhibited significantly reduced interferon activity on days 5 to 6 postchallenge. Supported by cellular and serological data, we conclude that blood interferon activity is a prominent marker that provides a convenient metric of influenza virus vaccine efficacy in the subclinical rhesus macaque model.

Published
2014

15. Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors

Author

Hartman, Lisa LR, Crawford, John R, Makale, Milan T, Milburn, Mehrzad, Joshi, Shweta, Salazar, Andres M, Hasenauer, Beth, VandenBerg, Scott R, MacDonald, Tobey J, and Durden, Donald L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Cancer, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Brain Disorders, Orphan Drug, Neurosciences, Pediatric, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Carboxymethylcellulose Sodium, Child, Child, Preschool, Dose-Response Relationship, Drug, Female, Glioma, Humans, Infant, Magnetic Resonance Angiography, Male, Neoplasm Grading, Poly I-C, Polylysine, Prospective Studies, Treatment Outcome, Young Adult, poly-ICLC, toll receptor, pediatric gliomas, phase I/II, toxicity, Cardiorespiratory Medicine and Haematology, Oncology & Carcinogenesis, Cardiovascular medicine and haematology
Abstract

Brain tumors are the most common solid tumor diagnosed in childhood that account for significant morbidity and mortality. New therapies are urgently needed; hence, we conducted the first ever prospective open-label phase II trials of the biological response modifier, poly-ICLC, in children with brain tumors. Poly-ICLC is a synthetic double-stranded RNA that has direct antiviral, antineoplastic, and immune adjuvant effects. A total of 47 children representing a variety of brain tumor histopathologic subtypes were treated with poly-ICLC. On the basis of the results of the initial phase II trial, an expanded prospective phase II trial in low-grade glioma (LGG) has been initiated. MRI was used to acquire volume-based measures of tumor response. No dose-limiting toxicities have been observed. In the initial study 3 of 12 subjects with progressive high-grade gliomas (HGGs) responded, and 2 of 4 children with progressive LGG experienced stable disease for 18 to 24 months. In the follow-up LGG phase II study, 2 of 5 LGG patients were stable over 18 months, with 1 stable for 6 months. Overall 5 of 10 LGG patients have responded. On the basis of low toxicity and the promising LGG response, poly-ICLC may be effective for childhood LGG, and the results justify biomarker studies for personalization of poly-ICLC as a single agent or adjuvant.

Published
2014

16. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.

Author

Saijo, Atsuro, Ogino, Hirokazu, Butowski, Nicholas A, Tedesco, Meghan R, Gibson, David, Watchmaker, Payal B, Okada, Kaori, Wang, Albert S, Shai, Anny, Salazar, Andres M, Molinaro, Annette M, Rabbitt, Jane E, Shahin, Maryam, Perry, Arie, Clarke, Jennifer L, Taylor, Jennie W, Daras, Mariza, Bush, Nancy Ann Oberheim, Hervey-Jumper, Shawn L, and Phillips, Joanna J

Published
2024
Full Text
View/download PDF

19. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Author

Keskin, Derin B., Anandappa, Annabelle J., Sun, Jing, Tirosh, Itay, Mathewson, Nathan D., Li, Shuqiang, Oliveira, Giacomo, Giobbie-Hurder, Anita, Felt, Kristen, Gjini, Evisa, Shukla, Sachet A., Hu, Zhuting, Li, Letitia, Le, Phuong M., Allesøe, Rosa L., Richman, Alyssa R., Kowalczyk, Monika S., Abdelrahman, Sara, Geduldig, Jack E., Charbonneau, Sarah, Pelton, Kristine, Iorgulescu, J. Bryan, Elagina, Liudmila, Zhang, Wandi, Olive, Oriol, McCluskey, Christine, Olsen, Lars R., Stevens, Jonathan, Lane, William J., Salazar, Andres M., Daley, Heather, Wen, Patrick Y., Chiocca, E. Antonio, Harden, Maegan, Lennon, Niall J., Gabriel, Stacey, Getz, Gad, Lander, Eric S., Regev, Aviv, Ritz, Jerome, Neuberg, Donna, Rodig, Scott J., Ligon, Keith L., Suvà, Mario L., Wucherpfennig, Kai W., Hacohen, Nir, Fritsch, Edward F., Livak, Kenneth J., Ott, Patrick A., Wu, Catherine J., and Reardon, David A.

Published
2019
Full Text
View/download PDF

21. Supplementary Figure Legend from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Author

Pavlick, Anna, primary, Blazquez, Ana B., primary, Meseck, Marcia, primary, Lattanzi, Michael, primary, Ott, Patrick A., primary, Marron, Thomas U., primary, Holman, Rose Marie, primary, Mandeli, John, primary, Salazar, Andres M., primary, McClain, Christopher B., primary, Gimenez, Gustavo, primary, Balan, Sreekumar, primary, Gnjatic, Sacha, primary, Sabado, Rachel Lubong, primary, and Bhardwaj, Nina, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Fig 2 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Author

Pavlick, Anna, primary, Blazquez, Ana B., primary, Meseck, Marcia, primary, Lattanzi, Michael, primary, Ott, Patrick A., primary, Marron, Thomas U., primary, Holman, Rose Marie, primary, Mandeli, John, primary, Salazar, Andres M., primary, McClain, Christopher B., primary, Gimenez, Gustavo, primary, Balan, Sreekumar, primary, Gnjatic, Sacha, primary, Sabado, Rachel Lubong, primary, and Bhardwaj, Nina, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Author

Pavlick, Anna, primary, Blazquez, Ana B., primary, Meseck, Marcia, primary, Lattanzi, Michael, primary, Ott, Patrick A., primary, Marron, Thomas U., primary, Holman, Rose Marie, primary, Mandeli, John, primary, Salazar, Andres M., primary, McClain, Christopher B., primary, Gimenez, Gustavo, primary, Balan, Sreekumar, primary, Gnjatic, Sacha, primary, Sabado, Rachel Lubong, primary, and Bhardwaj, Nina, primary

Published
2023
Full Text
View/download PDF

24. Data from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Author

Pavlick, Anna, primary, Blazquez, Ana B., primary, Meseck, Marcia, primary, Lattanzi, Michael, primary, Ott, Patrick A., primary, Marron, Thomas U., primary, Holman, Rose Marie, primary, Mandeli, John, primary, Salazar, Andres M., primary, McClain, Christopher B., primary, Gimenez, Gustavo, primary, Balan, Sreekumar, primary, Gnjatic, Sacha, primary, Sabado, Rachel Lubong, primary, and Bhardwaj, Nina, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Fig 3 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Author

Pavlick, Anna, primary, Blazquez, Ana B., primary, Meseck, Marcia, primary, Lattanzi, Michael, primary, Ott, Patrick A., primary, Marron, Thomas U., primary, Holman, Rose Marie, primary, Mandeli, John, primary, Salazar, Andres M., primary, McClain, Christopher B., primary, Gimenez, Gustavo, primary, Balan, Sreekumar, primary, Gnjatic, Sacha, primary, Sabado, Rachel Lubong, primary, and Bhardwaj, Nina, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Fig 1 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Author

Pavlick, Anna, primary, Blazquez, Ana B., primary, Meseck, Marcia, primary, Lattanzi, Michael, primary, Ott, Patrick A., primary, Marron, Thomas U., primary, Holman, Rose Marie, primary, Mandeli, John, primary, Salazar, Andres M., primary, McClain, Christopher B., primary, Gimenez, Gustavo, primary, Balan, Sreekumar, primary, Gnjatic, Sacha, primary, Sabado, Rachel Lubong, primary, and Bhardwaj, Nina, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

Author

Murphy, Katherine A., primary, Lechner, Melissa G., primary, Popescu, Flavia E., primary, Bedi, Jessica, primary, Decker, Stacy A., primary, Hu, Peisheng, primary, Erickson, Jami R., primary, O'Sullivan, M. Gerard, primary, Swier, Lauryn, primary, Salazar, Andres M., primary, Olin, Michael R., primary, Epstein, Alan L., primary, and Ohlfest, John R., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 6 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

Author

Murphy, Katherine A., primary, Lechner, Melissa G., primary, Popescu, Flavia E., primary, Bedi, Jessica, primary, Decker, Stacy A., primary, Hu, Peisheng, primary, Erickson, Jami R., primary, O'Sullivan, M. Gerard, primary, Swier, Lauryn, primary, Salazar, Andres M., primary, Olin, Michael R., primary, Epstein, Alan L., primary, and Ohlfest, John R., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 5 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

Author

Murphy, Katherine A., primary, Lechner, Melissa G., primary, Popescu, Flavia E., primary, Bedi, Jessica, primary, Decker, Stacy A., primary, Hu, Peisheng, primary, Erickson, Jami R., primary, O'Sullivan, M. Gerard, primary, Swier, Lauryn, primary, Salazar, Andres M., primary, Olin, Michael R., primary, Epstein, Alan L., primary, and Ohlfest, John R., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 2 from Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC

Author

Okada, Hideho, primary, Butterfield, Lisa H., primary, Hamilton, Ronald L., primary, Hoji, Aki, primary, Sakaki, Masashi, primary, Ahn, Brian J., primary, Kohanbash, Gary, primary, Drappatz, Jan, primary, Engh, Johnathan, primary, Amankulor, Nduka, primary, Lively, Mark O., primary, Chan, Michael D., primary, Salazar, Andres M., primary, Shaw, Edward G., primary, Potter, Douglas M., primary, and Lieberman, Frank S., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Author

Sabbatini, Paul, primary, Tsuji, Takemasa, primary, Ferran, Luis, primary, Ritter, Erika, primary, Sedrak, Christine, primary, Tuballes, Kevin, primary, Jungbluth, Achim A., primary, Ritter, Gerd, primary, Aghajanian, Carol, primary, Bell-McGuinn, Katherine, primary, Hensley, Martee L., primary, Konner, Jason, primary, Tew, William, primary, Spriggs, David R., primary, Hoffman, Eric W., primary, Venhaus, Ralph, primary, Pan, Linda, primary, Salazar, Andres M., primary, Diefenbach, Catherine Magid, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 1 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

Author

Murphy, Katherine A., primary, Lechner, Melissa G., primary, Popescu, Flavia E., primary, Bedi, Jessica, primary, Decker, Stacy A., primary, Hu, Peisheng, primary, Erickson, Jami R., primary, O'Sullivan, M. Gerard, primary, Swier, Lauryn, primary, Salazar, Andres M., primary, Olin, Michael R., primary, Epstein, Alan L., primary, and Ohlfest, John R., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Author

Sabbatini, Paul, primary, Tsuji, Takemasa, primary, Ferran, Luis, primary, Ritter, Erika, primary, Sedrak, Christine, primary, Tuballes, Kevin, primary, Jungbluth, Achim A., primary, Ritter, Gerd, primary, Aghajanian, Carol, primary, Bell-McGuinn, Katherine, primary, Hensley, Martee L., primary, Konner, Jason, primary, Tew, William, primary, Spriggs, David R., primary, Hoffman, Eric W., primary, Venhaus, Ralph, primary, Pan, Linda, primary, Salazar, Andres M., primary, Diefenbach, Catherine Magid, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure Legend from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Author

Sabbatini, Paul, primary, Tsuji, Takemasa, primary, Ferran, Luis, primary, Ritter, Erika, primary, Sedrak, Christine, primary, Tuballes, Kevin, primary, Jungbluth, Achim A., primary, Ritter, Gerd, primary, Aghajanian, Carol, primary, Bell-McGuinn, Katherine, primary, Hensley, Martee L., primary, Konner, Jason, primary, Tew, William, primary, Spriggs, David R., primary, Hoffman, Eric W., primary, Venhaus, Ralph, primary, Pan, Linda, primary, Salazar, Andres M., primary, Diefenbach, Catherine Magid, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Author

Sabbatini, Paul, primary, Tsuji, Takemasa, primary, Ferran, Luis, primary, Ritter, Erika, primary, Sedrak, Christine, primary, Tuballes, Kevin, primary, Jungbluth, Achim A., primary, Ritter, Gerd, primary, Aghajanian, Carol, primary, Bell-McGuinn, Katherine, primary, Hensley, Martee L., primary, Konner, Jason, primary, Tew, William, primary, Spriggs, David R., primary, Hoffman, Eric W., primary, Venhaus, Ralph, primary, Pan, Linda, primary, Salazar, Andres M., primary, Diefenbach, Catherine Magid, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 2 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 3 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

Author

Murphy, Katherine A., primary, Lechner, Melissa G., primary, Popescu, Flavia E., primary, Bedi, Jessica, primary, Decker, Stacy A., primary, Hu, Peisheng, primary, Erickson, Jami R., primary, O'Sullivan, M. Gerard, primary, Swier, Lauryn, primary, Salazar, Andres M., primary, Olin, Michael R., primary, Epstein, Alan L., primary, and Ohlfest, John R., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure Legends from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure Legend from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

Author

Murphy, Katherine A., primary, Lechner, Melissa G., primary, Popescu, Flavia E., primary, Bedi, Jessica, primary, Decker, Stacy A., primary, Hu, Peisheng, primary, Erickson, Jami R., primary, O'Sullivan, M. Gerard, primary, Swier, Lauryn, primary, Salazar, Andres M., primary, Olin, Michael R., primary, Epstein, Alan L., primary, and Ohlfest, John R., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 4 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

Author

Murphy, Katherine A., primary, Lechner, Melissa G., primary, Popescu, Flavia E., primary, Bedi, Jessica, primary, Decker, Stacy A., primary, Hu, Peisheng, primary, Erickson, Jami R., primary, O'Sullivan, M. Gerard, primary, Swier, Lauryn, primary, Salazar, Andres M., primary, Olin, Michael R., primary, Epstein, Alan L., primary, and Ohlfest, John R., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 3 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 3 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Author

Sabbatini, Paul, primary, Tsuji, Takemasa, primary, Ferran, Luis, primary, Ritter, Erika, primary, Sedrak, Christine, primary, Tuballes, Kevin, primary, Jungbluth, Achim A., primary, Ritter, Gerd, primary, Aghajanian, Carol, primary, Bell-McGuinn, Katherine, primary, Hensley, Martee L., primary, Konner, Jason, primary, Tew, William, primary, Spriggs, David R., primary, Hoffman, Eric W., primary, Venhaus, Ralph, primary, Pan, Linda, primary, Salazar, Andres M., primary, Diefenbach, Catherine Magid, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results